Becton, Dickinson and Company (NYSE:BDX) Given Average Rating of “Hold” by Brokerages

Shares of Becton, Dickinson and Company (NYSE:BDX) have been assigned an average rating of “Hold” from the sixteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $181.00.

A number of brokerages have recently commented on BDX. Barclays raised their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. TD Cowen dropped their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. Argus reduced their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Piper Sandler decreased their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th.

Becton, Dickinson and Company Stock Down 0.2%

NYSE:BDX opened at $145.28 on Wednesday. The company has a market cap of $40.03 billion, a price-to-earnings ratio of 36.78, a price-to-earnings-growth ratio of 10.30 and a beta of 0.22. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $149.64 and a 200-day simple moving average of $173.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the transaction, the executive vice president owned 14,272 shares of the company’s stock, valued at approximately $2,161,922.56. This represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,013 shares of company stock worth $593,434 in the last three months. Corporate insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth $25,000. Steph & Co. lifted its stake in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the last quarter. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $26,000. Meeder Asset Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the last quarter. Finally, Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $29,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.